Ibogaine research review highlights safety concerns

Thirty years of ibogaine research reviewed

A comprehensive review of ibogaine research over the past three decades highlights both its potential therapeutic benefits and significant safety concerns, according to a study published in the Journal of Clinical Psychopharmacology. The review, conducted by Ewen Kervadec and colleagues, examined clinical studies on ibogaine from 1990 to February 2025, focusing on its use in treating substance use and psychiatric disorders.

What the study found

The review included 24 studies and 38 case reports or series, revealing that most positive efficacy data come from uncontrolled or retrospective studies, often conducted outside clinical settings. These studies, which carry a high risk of bias, suggest ibogaine may alleviate symptoms of opioid use disorder (OUD), PTSD, and polysubstance dependence. However, no double-blind randomized controlled trial (RCT) has yet confirmed ibogaine's efficacy in treating OUD. Only one small RCT showed significant effects for cocaine use disorder.

Safety concerns

The study underscores serious safety concerns associated with ibogaine, particularly cardiotoxicity due to QT prolongation. This risk is significant given the lack of proven efficacy in clinical settings. The review emphasizes the need for further research to optimize ibogaine's safety profile and determine its potential role in psychiatric care.

Why it matters

Ibogaine has been a compound of interest in neuropsychiatric research due to its potential therapeutic properties. However, the current evidence is insufficient to support its clinical use, particularly in light of the safety risks identified. As interest in psychedelic therapies grows, understanding ibogaine's efficacy and safety is crucial for its potential integration into psychiatric treatment.

Further studies are necessary to establish ibogaine's therapeutic value and ensure its safe application in clinical settings.